Cannabis Science Launches a Global Consortium and Announces

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
137
Cannabis Science Launches a Global Consortium and Announces Updates on Its Drug Development Initiatives and Research Collaborations

IRVINE, CA--(Marketwired - Aug 23, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the launch of the Cannabis Science Global Consortium and to provide updates on the Company's drug development initiatives and research collaborations.

The Cannabis Science Global Consortium provides the Company with a framework to cooperate and collaborate with stakeholders worldwide. "The objective of our consortium is to harness the collective expertise of our global partners to investigate the use of Cannabinoids for the treatment of a variety of indications, including cancers, neurological conditions, pain management, the treatment of HIV and AIDS, and epilepsy," stated Mr. Raymond C. Dabney, President, Chief Executive Officer, Co-founder, and Director of Cannabis Science. "The Cannabis Science Global Consortium will link universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside." The Cannabis Science Global Consortium will also enable the Company to more strategically coordinate its initiatives, including those focused on education, job creation, and skills training.

 Cannabis Science is aggressively expanding the Company's network of research centers. Negotiations are ongoing with several academic institutions in the United States and internationally to establish new, collaborative research agreements. These contracts will focus on several indications, and are expected to expand the research funded and directed by the Company. In addition, Cannabis Science will develop multi-center, clinical trial networks with cannabinoid drug development.

 Cannabis Science currently has several research programs underway that have produced initial results that are critical in the Company's early phase cancer drug development plan. "These initial results are better than expected and are helping Cannabis Science refine our drug development program," stated Dr. Allen Herman, Chief Medical Officer of Cannabis Science. "Based on our progress to date, we expect to conclude pre-clinical work on a few cannabinoids over the next several months, and begin clinical trials in 2018. This timeline is consistent with the Company's overall development strategy."

 There are three primary elements in Cannabis Science's drug development program: (1) Defining the effectiveness and specificity of cannabinoids being tested; (2) Identifying and testing drug delivery mechanisms; and (3) Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in our randomized controlled trials. The Company's initial results point to the importance of drug delivery systems and the impact of co-interventions.

 "These initial experiments follow the outlines of the proposed research described in the 2016 National Academies of Sciences, Engineering, and Medicine Report on the use of Cannabinoids in medical care," said Dr. Herman "This work defines the vital early steps in our drug development program that will bring new pharmaceuticals to the treatment of many diseases."

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Cannabis Science, Inc. Dr. Allen Herman Chief Medical Officer (CMO) allen.herman@cannabisscience.com Tel: 1-888-263-0832 Cannabis Science, Inc. Mr. Raymond C. Dabney President & CEO, Co-Founder raymond.dabney@cannabisscience.com Tel: 1-888-263-0832

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 169

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 82

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 46

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 22

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 69

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 189

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 150

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 247

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Edward H. McKay Takes Helm as New CEO of Shenandoah Telecommunications

Updated Category News Views 218

Leadership Change at Shenandoah Telecommunications Shenandoah Telecommunications Company, often referred to as "Shentel," has officially announced a significant leadership transition. Edward H. "Ed" McKay has been appointed as the new President and Chief Executive Officer. This change is set to take place on a specified date in the near future, as current President and...

Continue Reading
Projected Growth of Security Printing Market to USD 5.79 Billion

Updated Category News Views 118

Security Printing Market Overview SkyQuest has forecasted that the global security printing market will achieve a remarkable valuation of USD 5.79 billion by the year 2031. This represents a compound annual growth rate (CAGR) of 3.10% during the projection period, which spans from 2024 to 2031. The driving force behind this growth is the collective efforts of governments...

Continue Reading
Prosperity Bancshares, Inc. and Southwest Bancshares Unite

Updated Category News Views 136

Prosperity Bancshares, Inc. Merges with Southwest Bancshares In an exciting development for the banking sector, Prosperity Bancshares, Inc. has officially completed its merger with Southwest Bancshares, Inc. This strategic consolidation promises to bring enhanced customer service and a richer array of financial products, benefiting customers in various ways. As the...

Continue Reading
Revolutionizing AI Security Standards: Wallarm's A2AS Framework

Updated Category News Views 970

Wallarm's Role in Advancing AI Security Today, Wallarm announced its significant contribution to the release of "A2AS: Agentic AI Runtime Security and Self-Defense." This innovative project, spearheaded by Eugene Neelou, aligns various industry leaders, including AWS, Cisco, Google, and more, to fortify the foundation of AI security protocols. The A2AS Framework: A New...

Continue Reading
R2 Wireless Expands Operations with New US Leadership Team

Updated Category News Views 355

R2 Wireless Expands Operations with New Leadership R2 has made a significant stride in addressing the increasing threats and advancements in Electronic Warfare and Counter-UAS programs. The company has launched its US operations and appointed Mr. Cordell Bennigson as its US CEO. Strategic Move for Growth This strategic decision comes in response to the rising global...

Continue Reading